Diffuse Midline Glioma: Understanding Why Pediatric Brain Tumors Relapse After Radiation
Official title: Research Project 1: Diffuse Midline Glioma
Funded at Dana-Farber Cancer Inst · NIH-11415783 · Data updated 2026-11-12
A researcher team is studying why certain pediatric brain tumors called diffuse midline gliomas resist and come back after radiotherapy, to help develop better treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $261,411 |
| NIH project number | 5U54CA274516-04 |
| Project ID | NIH-11415783 on NIH RePORTER |
Who could benefit from this research
✓Could help
Pediatric patients with diffuse midline glioma who are undergoing or have undergone radiotherapy and from whom paired tumor samples can be obtained.
✕Less likely to help
Patients without DMG or without access to paired pre- and post-radiation samples may not directly benefit.
What this research studies
This project looks at how the tumor environment and cellular diversity inside DMG tumors might cause radiation resistance. By using advanced single-cell analysis and DNA repair pathway studies on pre- and post-radiation samples, the team aims to map why some tumor cells survive. The work focuses on pediatric patients and uses data from tumor samples to connect biology with treatment outcomes. The goal is to identify new targets to improve radiotherapy effectiveness for DMG.
Why it matters
Potential benefit: If successful, findings could lead to more effective radiation approaches or combination therapies for children with DMG.
How similar studies have gone: Previous single-cell studies have shown heterogeneity in DMG, supporting the relevance of this approach, though direct translation to improved therapy is still emerging.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Haas-Kogan, Daphne a. — Dana-Farber Cancer Inst
- Study coordinator: Haas-Kogan, Daphne a.
Related research
Other NIH-funded projects on the same topics.
-
Next‑gen oncolytic virus therapy for glioblastoma targeting AKT and ERK
A new cancer therapy using an engineered oncolytic virus to fight glioblastoma by blocking AKT/ERK signals and boosting the body’s immune response, with potential to reduce seizures and improve quality of life.
-
Bone marrow immune cells and glioma progression in teens and young adults
A study in adolescents and young adults with brain tumors looks at how immune cells from bone marrow may influence the progression from low-grade to high-grade gliomas.
-
How RNA Splicing Might Shape Glioma Cell States and Therapy Response
A small NIH-funded project will study how alternative RNA splicing influences glioma cell identities and treatment resistance in patient-derived cells.
-
Liquid biopsy for monitoring high-grade glioma using patient-specific DNA junctions
A Mayo Clinic team tests a blood test that looks for unique tumor DNA pieces in glioblastoma patients to monitor disease without frequent scans.
-
Deciphering how a brain cell pH helper influences glioma growth
A study is exploring whether a brain cell pH regulator (Slc4a4) affects the growth and blood vessel changes of malignant glioma to identify new angles for treatment.
-
Predicting how gene therapy spreads in glioblastoma after surgery to improve treatment coverage
This project uses a gene therapy that helps radiation work better against glioblastoma and builds computer models to predict where the therapy reaches after surgical tumor removal.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.